Targeted therapies in the treatment of colorectal cancer

what managed care needs to know.

Rowena N. Schwartz, Charles Blanke, Larry John Pesko

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE: This review is designed to explore the disease, its current treatment, the expanding field of antiangiogenic treatments, and the implications of these advances for the managed care patient. DATA SOURCES: This article is based, in part, on presentations given by the authors in a continuing education symposium presented during the Academy of Managed Care Pharmacy.s 16th Annual Meeting and Showcase, April 1, 2004, in San Francisco. CONCLUSIONS: Colorectal cancer (CRC) is the third most common cancer in the United States, and the second-leading non.gender-specific cause of cancer deaths. If the cancer is caught soon enough (before node involvement and metastasis occur), there is a strong chance of survival; however, only slightly more than one third of cases are detected that soon. Emerging treatments that target only the cancer cells are increasing the length of survival for those who are diagnosed at later stages of the disease.

Original languageEnglish (US)
JournalJournal of managed care pharmacy : JMCP
Volume10
Issue number5 Suppl B
StatePublished - Oct 2004
Externally publishedYes

Fingerprint

Managed Care Programs
Colorectal Neoplasms
Neoplasms
Education
Cells
San Francisco
Survival
Continuing Education
Therapeutics
Cause of Death
Neoplasm Metastasis

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Health Policy
  • Pharmacy

Cite this

Targeted therapies in the treatment of colorectal cancer : what managed care needs to know. / Schwartz, Rowena N.; Blanke, Charles; Pesko, Larry John.

In: Journal of managed care pharmacy : JMCP, Vol. 10, No. 5 Suppl B, 10.2004.

Research output: Contribution to journalArticle

@article{39e5d993171a44c09637322fa36864ff,
title = "Targeted therapies in the treatment of colorectal cancer: what managed care needs to know.",
abstract = "OBJECTIVE: This review is designed to explore the disease, its current treatment, the expanding field of antiangiogenic treatments, and the implications of these advances for the managed care patient. DATA SOURCES: This article is based, in part, on presentations given by the authors in a continuing education symposium presented during the Academy of Managed Care Pharmacy.s 16th Annual Meeting and Showcase, April 1, 2004, in San Francisco. CONCLUSIONS: Colorectal cancer (CRC) is the third most common cancer in the United States, and the second-leading non.gender-specific cause of cancer deaths. If the cancer is caught soon enough (before node involvement and metastasis occur), there is a strong chance of survival; however, only slightly more than one third of cases are detected that soon. Emerging treatments that target only the cancer cells are increasing the length of survival for those who are diagnosed at later stages of the disease.",
author = "Schwartz, {Rowena N.} and Charles Blanke and Pesko, {Larry John}",
year = "2004",
month = "10",
language = "English (US)",
volume = "10",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "5 Suppl B",

}

TY - JOUR

T1 - Targeted therapies in the treatment of colorectal cancer

T2 - what managed care needs to know.

AU - Schwartz, Rowena N.

AU - Blanke, Charles

AU - Pesko, Larry John

PY - 2004/10

Y1 - 2004/10

N2 - OBJECTIVE: This review is designed to explore the disease, its current treatment, the expanding field of antiangiogenic treatments, and the implications of these advances for the managed care patient. DATA SOURCES: This article is based, in part, on presentations given by the authors in a continuing education symposium presented during the Academy of Managed Care Pharmacy.s 16th Annual Meeting and Showcase, April 1, 2004, in San Francisco. CONCLUSIONS: Colorectal cancer (CRC) is the third most common cancer in the United States, and the second-leading non.gender-specific cause of cancer deaths. If the cancer is caught soon enough (before node involvement and metastasis occur), there is a strong chance of survival; however, only slightly more than one third of cases are detected that soon. Emerging treatments that target only the cancer cells are increasing the length of survival for those who are diagnosed at later stages of the disease.

AB - OBJECTIVE: This review is designed to explore the disease, its current treatment, the expanding field of antiangiogenic treatments, and the implications of these advances for the managed care patient. DATA SOURCES: This article is based, in part, on presentations given by the authors in a continuing education symposium presented during the Academy of Managed Care Pharmacy.s 16th Annual Meeting and Showcase, April 1, 2004, in San Francisco. CONCLUSIONS: Colorectal cancer (CRC) is the third most common cancer in the United States, and the second-leading non.gender-specific cause of cancer deaths. If the cancer is caught soon enough (before node involvement and metastasis occur), there is a strong chance of survival; however, only slightly more than one third of cases are detected that soon. Emerging treatments that target only the cancer cells are increasing the length of survival for those who are diagnosed at later stages of the disease.

UR - http://www.scopus.com/inward/record.url?scp=16544380361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544380361&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 5 Suppl B

ER -